BioCryst's $235m BARDA-funded flu drug unlikely to progress in US
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals has said it is unlikely to continue development for US registration of its viral neuraminidase inhibitor, peramivir, as a treatment for seasonal influenza after an independent data monitoring committee (DMC) recommended that a Phase III of the drug study be terminated for futility.